Welcome to our dedicated page for Legend Biotech news (Ticker: LEGN), a resource for investors and traders seeking the latest updates and insights on Legend Biotech stock.
Legend Biotech Corporation reports news on cell therapy development and commercialization, centered on CARVYKTI® (ciltacabtagene autoleucel), a CAR-T therapy for relapsed or refractory multiple myeloma developed and marketed with Johnson & Johnson. Company updates commonly cover CARVYKTI sales trends, treatment-site expansion, manufacturing capacity, clinical and real-world data from the CARTITUDE program, and label or evidence developments tied to multiple myeloma care.
Legend Biotech news also follows its broader cell therapy pipeline, including allogeneic and in vivo CAR-T programs such as LUCAR-G39D in B-cell non-Hodgkin lymphoma. Recurring announcements include quarterly financial results, scientific-conference presentations, research and manufacturing priorities, advisory input, and corporate governance updates.
Legend Biotech (NASDAQ: LEGN) reported first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T for relapsed/refractory B-cell non-Hodgkin lymphoma.
In a 12-patient Phase 1 study, dose level 2 achieved 100% ORR and 83.3% CR with ongoing responses and a favorable safety profile without lymphodepletion.
Legend Biotech (NASDAQ: LEGN) reported first clinical proof-of-concept for LB2501, an investigational in vivo CD19/CD20 dual-targeting CAR-T, in relapsed/refractory B-cell non-Hodgkin lymphoma. In a Phase 1 trial, a single infusion at the higher dose achieved 100% ORR and 83.3% CR without lymphodepletion.
LB2501 showed dose-dependent in vivo CAR-T expansion, Grade 1–2 IRR/CRS only, no DLTs, SAEs, ICANS, or deaths, plus rapid vector clearance and polyclonal vector integration.
Legend Biotech (NASDAQ: LEGN) will present initial Phase 1 data for LB2501, an in vivo CD19/CD20 dual-targeting CAR-T therapy, at EHA 2026 in R/R B-cell NHL.
At dose level 2, ORR was 100% (6/6) with CR rate 83.3% (5/6), all ongoing at cutoff, with dose-dependent in vivo CAR-T expansion and no DLTs, SAEs, deaths or ICANS reported. CRS and infusion reactions were ≤ Grade 2.
Legend Biotech (NASDAQ: LEGN) reported first-in-human Phase 1 data for LB2102 in relapsed/refractory SCLC or LCNEC and new CARVYKTI findings at ASCO 2026.
LB2102 showed ORR 20% and DCR 70% (ORR 28.6%, DCR 78.6% at higher doses) with manageable safety. Updated CARTITUDE data reinforced CARVYKTI’s durable benefit, 30‑month OS >85% in a key subgroup, low IEC‑enterocolitis incidence (1.2%), and consistent safety in multiple myeloma.
Legend Biotech (NASDAQ: LEGN) will present multiple CAR-T data sets at the ASCO 2026 Annual Meeting. Highlights include a rapid oral presentation of preliminary Phase 1 data for LB2102 in relapsed or refractory SCLC/LCNEC, new CARTITUDE‑4 cytogenetic subgroup analyses for CARVYKTI, and an IEC‑EC safety analysis.
The company will also host an in‑person investor event and live webcast on Sunday, May 31, 2026, at 6:15 p.m. CT in Chicago.
Legend Biotech (NASDAQ: LEGN) reported strong CARVYKTI® growth for Q1 2026, with net trade sales up 62% year-over-year to approximately $597 million and availability in 18 markets and 300+ sites.
Collaboration revenue reached $298.4 million, cash was $834.6 million, and net loss narrowed to $54.3 million, with adjusted net loss at $10.5 million. The company achieved $55 million in Janssen milestones and reports improving margins and manufacturing metrics.
Legend Biotech (NASDAQ: LEGN) announced on May 4, 2026 the engagement of a group of scientific advisors to guide its cell therapy pipeline and research priorities. The advisors bring expertise in oncology, immunology, development, and manufacturing to inform translational research, clinical development, and manufacturing strategy.
The panel aims to support Legend's evolution toward a diversified, next-generation cell therapy pipeline focused on areas of high unmet medical need and expanding patient access.
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, May 12, 2026 to review first quarter 2026 financial results. Senior management will provide an overview of quarterly financial performance via live audio webcast.
A replay and the earnings press release will be available in the Investor Relations section under Events and Presentation approximately two hours after the call concludes.
Legend Biotech (NASDAQ: LEGN) reported Q4 2025 CARVYKTI net trade sales of approximately $555 million and full-year 2025 sales of $1.9 billion, achieved franchise profitability for 2025, and reached >10,000 patients treated. Cash and time deposits were $949 million as of December 31, 2025. The company expanded manufacturing capacity and global commercial footprint, reported improved operating loss versus prior year, and highlighted progress across allogeneic and in vivo pipelines.
Legend Biotech (NASDAQ: LEGN) will host an investor conference call at 8:00 am ET on Tuesday, March 10, 2026 to review fourth-quarter and full-year 2025 results. The call includes a live audio webcast and a replay plus the earnings release available in Investor Relations approximately two hours after the call.
Investors can access the live webcast via the company link; management will provide an overview of quarterly and full-year financial performance.